
Johnson & Johnson (JNJ.N) is required to add new warnings to its diabetes drug, Invokana
Advertisements
The FDA noted that results of one clinical trial showed that over the course of a year the risk of amputation in patients treated with Invokana was equivalent to 5.9 out of 1,000, compared with 2.8 out of 1,000 for patients given a placebo.
Source: REUTERS